{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Islam W"],"funding":["Ministry of Health, Labour and Welfare","Japan Science and Technology Agency","Japan Society for the Promotion of Science"],"pagination":["487"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8229906"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(6)"],"pubmed_abstract":["For more than three decades, enhanced permeability and retention (EPR)-effect-based nanomedicines have received considerable attention for tumor-selective treatment of solid tumors. However, treatment of advanced cancers remains a huge challenge in clinical situations because of occluded or embolized tumor blood vessels, which lead to so-called heterogeneity of the EPR effect. We previously developed a method to restore impaired blood flow in blood vessels by using nitric oxide donors and other agents called EPR-effect enhancers. Here, we show that two novel EPR-effect enhancers-isosorbide dinitrate (ISDN, Nitrol®) and sildenafil citrate-strongly potentiated delivery of three macromolecular drugs to tumors: a complex of poly(styrene-co-maleic acid) (SMA) and cisplatin, named Smaplatin® (ch"],"journal":["Journal of personalized medicine"],"pubmed_title":["EPR-Effect Enhancers Strongly Potentiate Tumor-Targeted Delivery of Nanomedicines to Advanced Cancers: Further Extension to Enhancement of the Therapeutic Effect."],"pmcid":["PMC8229906"],"funding_grant_id":["29400001","17016076","AS242Z01542Q","General 001","18H04059"],"pubmed_authors":["Niidome T","Maeda H","Islam R","Fang J","Kimura S","Islam W","Ono K","Harada A","Sawa T"],"additional_accession":[]},"is_claimable":false,"name":"EPR-Effect Enhancers Strongly Potentiate Tumor-Targeted Delivery of Nanomedicines to Advanced Cancers: Further Extension to Enhancement of the Therapeutic Effect.","description":"For more than three decades, enhanced permeability and retention (EPR)-effect-based nanomedicines have received considerable attention for tumor-selective treatment of solid tumors. However, treatment of advanced cancers remains a huge challenge in clinical situations because of occluded or embolized tumor blood vessels, which lead to so-called heterogeneity of the EPR effect. We previously developed a method to restore impaired blood flow in blood vessels by using nitric oxide donors and other agents called EPR-effect enhancers. Here, we show that two novel EPR-effect enhancers-isosorbide dinitrate (ISDN, Nitrol®) and sildenafil citrate-strongly potentiated delivery of three macromolecular drugs to tumors: a complex of poly(styrene-co-maleic acid) (SMA) and cisplatin, named Smaplatin® (ch","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 May","modification":"2025-04-19T17:43:34.341Z","creation":"2022-02-10T18:48:43.173Z"},"accession":"S-EPMC8229906","cross_references":{"pubmed":["34071552"],"doi":["10.3390/jpm11060487"]}}